Based on this YouTube video's total view count of 621 views and industry-standard rates, the estimated total earning is $0 - $1 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCL with 621 views, 6 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Monash University, Monash Health, Melbourne, Australia, discusses the Phase III STARGLO trial (NCT04408638), evaluating glofitamab in combination with gemcitabine and oxaliplatin vs rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The primary endpoint of the trial was met, with the combination including glofitamab having a significant clinical benefit in overall survival (OS) and a manageable toxicity profile. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.